On Friday, Following U.S. Stocks were among the “Top Gainers”: Memorial Resource Development Corp (NASDAQ:MRD), Imperva Inc (NYSE:IMPV), BioCryst Pharmaceuticals, Inc (NASDAQ:BCRX), Progenics Pharmaceuticals, Inc (NASDAQ:PGNX)
Memorial Resource Development Corp (NASDAQ:MRD), with shares inclined 5.60%, closed at $17.54.
Imperva Inc (NYSE:IMPV), with shares jumped 5.23%, settled at $42.03.
BioCryst Pharmaceuticals, Inc (NASDAQ:BCRX), with shares climbed 4.75%, and closed at $10.03.
Progenics Pharmaceuticals, Inc (NASDAQ:PGNX), surged 4.73%, and closed at $7.09.
Latest NEWS regarding these Stocks are depicted underneath:
Memorial Resource Development Corp. (NASDAQ:MRD)
Memorial Resource Development Corp. (MRD), declared its operating and financial results for the fourth quarter and year ended December 31, 2014.
Full Year 2014 Results:
Net production raised 77% year-over-year to 227 MMcfe/d for 2014 contrast to 128 MMcfe/d for 2013. 2014 net production comprised of 175 MMcf/d of natural gas (77%), 6.1 MBbls/d of NGLs (16%) and 2.6 MBbls/d of crude oil (7%). During 2014, MRD brought online 42 gross wells, compriseing of 34 wells in the Terryville Field, 6 in East Texas, and 2 in the Rockies. In the Terryville Field, MRD accomplished 31 horizontal wells in its four primary, over-pressured Lower Cotton Valley zones, one horizontal well in an Upper Cotton Valley zone and two vertical wells.
Total proceeds raised 75% to $405.3 million during 2014 from $231.6 million for 2013. The raise was primarily due to drilling activity in North Louisiana and East Texas.
MRD’s realized pricing varies from NYMEX due to proceed deductions for the net costs of gathering, transporting and processing and regional basis differentials.
LOE for the year was $26.7 million, or $0.32 per Mcfe, contrast to $25.0 million, or $0.53 per Mcfe, in 2013. The decrease in per unit LOE resulted from raised sales volumes, lower per unit operating cost attributable to pad development and MRD’s continuous efforts to reduce costs.
Production and ad valorem taxes were $14.1 million for 2014, or $0.17 per Mcfe, contrast to $9.4 million, or $0.20 per Mcfe, for the previous year. 2014 production and ad valorem taxes raised as compared to 2013 due to higher production and associated proceed.
G&A expense for 2014 was $42.1 million, or $0.51 per Mcfe, contrast to $38.5 million, or $0.82 per Mcfe, for 2013. During 2014, G&A expense comprised of $2.8 million, or $0.03 per Mcfe, of stock-based compensation expense and $2.3 million, or $0.03 per Mcfe, of attainment related costs. This compares to $1.6 million, or $0.03 per Mcfe, of attainment related costs for the preceding year period.
Net interest expense during 2014 was $50.3 million, counting amortization of deferred financing fees of about $3.2 million. This compares to net interest expense during 2013 of $27.3 million, counting amortization of deferred financing fees of about $2.5 million. The year-over-year rise in net interest expense is primarily the result of long term debt associated with MRD’s senior unsecured notes.
Capital expenditures totaled $517.5 million for the year ended December 31, 2014 and comprised of $97.8 million related to attainments. In 2014, MRD spent about 90% in the Terryville Field, 5% in East Texas and 5% in the Rockies.
Memorial Resource Development Corp., an independent natural gas and oil corporation, focuses on the attainment, exploitation, and development of natural gas, natural gas liquids, and oil properties in North Louisiana, in addition to the Rocky Mountains.
Imperva Inc. (NYSE:IMPV)
Imperva Inc. (IMPV), declared the pricing of its underwritten registered public follow-on offering of 3,000,000 shares of its ordinary stock at a price to the public of $39.00 per share. Imperva also granted the underwriters a 30-day option to purchase up to an additional 450,000 shares of its ordinary stock. The offering is predictable to close on March 18, 2015, subject to customary closing conditions.
Imperva anticipates to use the net proceeds from the offering for working capital and other general corporate purposes, which may comprise attainments of businesses, technologies or other assets, although Imperva presently has no contracts or commitments regarding specific attainments at this time. Morgan Stanley & Co. LLC, Deutsche Bank Securities Inc., RBC Capital Markets LLC and Pacific Crest Securities LLC are acting as book-runners for the offering. Macquarie Capital (USA) Inc. and Nomura Securities International, Inc. are acting as co-managers.
An effective registration statement regarding these securities was filed with the Securities and Exchange Commission on March 9, 2015. The offering is being made only by means of an effective shelf registration statement, counting a preliminary prospectus, and final prospectus, copies of which may be obtained by contacting Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014.
Imperva, Inc. develops, markets, sells, services, and supports cyber security solutions that protect business critical data and applications in the cloud or on premises worldwide.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
BioCryst Pharmaceuticals, Inc. (BCRX), provided a corporate update regarding the Corporation’s clinical programs at the following investor conferences:
The 27th Annual ROTH Conference in Laguna Niguel, CA on Monday, March 9, 2015.
The Barclays Global Healthcare Conference in Miami, FL on Thursday, March 12, 2015.
BioCryst Pharmaceuticals, Inc., a biotechnology corporation, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. BioCryst presently has several ongoing development programs: oral inhibitors of plasma kallikrein for hereditary angioedema, counting BCX4161, BCX7353 and other second generation compounds, and BCX4430, a broad spectrum viral RNA polymerase inhibitor.
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)
Progenics Pharmaceuticals, Inc. (PGNX), declared that it will host a conference call and webcast to review fourth quarter and year end 2014 financial results on Monday, March 16, at 8:30 a.m. ET.
To take part, please dial (877) 250-8889 (domestic) or (720) 545-0001 (international) and reference conference ID 89741044.
Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that comprises several product candidates in later-stage clinical development. Progenics’ first-in-class PSMA-targeted technology platform for prostate cancer comprises an antibody drug conjugate therapeutic which accomplished a two-cohort phase 2 clinical trial and a small molecule imaging agent that has also accomplished a phase 2 trial.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
